Related Experiment Video
Updated: May 3, 2026

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
Published on: June 2, 2019
Sitagliptin ameliorates lipid profile changes and endothelium dysfunction induced by atherogenic diet in rabbits
1Pharmacology and Toxicology Department, College of Pharmacy, Taibah University, El-Madinah El-Munawarah, KSA, manarahna@yahoo.com.
Abstract:
The aim of this work was to investigate the effect of sitagliptin on lipid profile and endothelium function in rabbits. Rabbits were fed either normal chow or atherogenic diet for 10 weeks. Sitagliptin (6 mg/kg/twice daily) was given orally for 6 weeks starting from week 4. Blood samples were collected at day 0, week 4, and week 10 to measure serum lipid profile, nitrate/nitrite (NOx), lactate dehydrogenase (LDH), and malondialdehyde (MDA) levels. The aortic arch and thoracic aorta were excised and used for histological study and isolated vascular preparations, respectively. Sitagliptin treatment significantly reduced the levels of low density lipoprotein cholesterol, NOx, total cholesterol, and MDA, but not triglyceridess. Additionally, sitagliptin markedly reversed the decrease in high-density lipoprotein cholesterol level. Moreover, sitagliptin significantly improved the impaired endothelium-dependent relaxation, without affecting phenylepherine-induced contraction and sodium nitroprusside-induced endothelium-independent relaxation in isolated aortic rings. Histopathological examination revealed marked reduction of the atherosclerotic lesions by sitagliptin. Immunohistochemical analysis of nuclear factor-kappa B in aortic tissue showed marked reduction in its expression upon treatment with sitagliptin compared with atherogenic diet-fed rabbits. These results suggest that sitagliptin may be an effective pharmacological approach for preventing atherosclerotic lesion progression in rabbits.
More Related Videos
10:31An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
Published on: April 20, 2018
09:14The Rabbit Model of Accelerated Atherosclerosis: A Methodological Perspective of the Iliac Artery Balloon Injury
Published on: October 3, 2017
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Atherosclerosis III: Management
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents